Active	Status	Sponsor type	Region	Phase	Filter
9 Active 2 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mantzaris, Ioannis
SY-1425-202, NCT04905407: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML	Recruiting	2	95	Europe, US	Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza	Syros Pharmaceuticals	Acute Myeloid Leukemia	04/28	04/28
NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Jul 2023 - Dec 2023: Preliminary data from trial in combination with ZN-d5 for r/r/ AML	Recruiting	1/2	95	US	ZN-d5 ZN-c3, Study Drug, ZN-c3	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.	Acute Myeloid Leukemia (AML)	03/25	02/26
NCT05342584: Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS	Recruiting	1b	99	US	Venetoclax Oral Tablet, Daunorubicin, Cytarabine	Ioannis Mantzaris, AbbVie	Acute Myeloid Leukemia, Myelodysplastic Syndromes	12/28	12/28